Terbufibrol |
| Katalog-Nr.GC31457 |
Terbufibrol hat sich bei der Senkung des Gesamtcholesterinspiegels (TC) im Serum bei normalen und hypercholesterinÄmischen mÄnnlichen Ratten als hochwirksam erwiesen.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 56488-59-6
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Terbufibrol has been shown highly active in reducing serum total cholesterol (TC) levels in the normal and hypercholesterolemic male rat.
Terbufibrol (20-200 mg/kg) is active in lowering serum TC in animals on all 3 diets, but the extent of cholesterol reduction varies in the order cholesterol (HC)>high protein and fat diet (HPF)>N (max. reductions: 154, 80, and 70%, respectively). Clofibrate (200 mg/kg) decreases TC by a maximum of 28% with the HPF-diet and 13% with the N-diet but is inactive with the HC-diet. Cholestyramine (400 mg/kg/day) is inactive in HPF-fed animals but reduces TC in HC-fed animals by 45%. With the HPF-diet nicotinic acid (200 mg/kg) is inactive. Terbufibrol lowers HDL, HDL-TC, LDL, LDL-TC and LDL-TC/PL in animals fed HPF-diet. A greater decrease of LDL-TC occurres with increasing dose. The main effect of Clofibrate (200 mg/kg) is to reduce HDL and HDL-TC and to increase LDL[1].
[1]. Howard AN, et al. The hypocholesterolemic effect of terbufibrol and other drugs in normal and hypercholesterolemic baboons. Atherosclerosis. 1979 Apr;32(4):367-80.
Average Rating: 5 (Based on Reviews and 34 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *